The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

George L. Drusano

Ordway Research Institute

Albany

New York 12208

USA

[email]@aol.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Ordway Research Institute, Albany, New York 12208, USA. 2004
  • Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College and New York State Department of Health, Albany, USA. 2003
  • Division of Clinical Pharmacology, Department of Medicine, Albany Medical College, Albany, USA. 2000 - 2002
  • Department of Medicine, Albany Medical College, New York 12208, USA. 1998 - 2001

References

  1. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. Drusano, G.L., Preston, S.L., Fowler, C., Corrado, M., Weisinger, B., Kahn, J. J. Infect. Dis. (2004) [Pubmed]
  2. Prevention of resistance: a goal for dose selection for antimicrobial agents. Drusano, G.L. Clin. Infect. Dis. (2003) [Pubmed]
  3. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Drusano, G.L., Bilello, P.A., Symonds, W.T., Stein, D.S., McDowell, J., Bye, A., Bilello, J.A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  4. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation. Drusano, G.L., Preston, S.L., Gotfried, M.H., Danziger, L.H., Rodvold, K.A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  5. Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation. Drusano, G.L., Moore, K.H., Kleim, J.P., Prince, W., Bye, A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  6. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Drusano, G.L., Preston, S.L., Hardalo, C., Hare, R., Banfield, C., Andes, D., Vesga, O., Craig, W.A. Antimicrob. Agents Chemother. (2001) [Pubmed]
  7. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. Drusano, G.L., Bilello, J.A., Preston, S.L., O'Mara, E., Kaul, S., Schnittman, S., Echols, R. J. Infect. Dis. (2001) [Pubmed]
  8. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Drusano, G.L., Preston, S.L., Smee, D., Bush, K., Bailey, K., Sidwell, R.W. Antimicrob. Agents Chemother. (2001) [Pubmed]
  9. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Drusano, G. Clin. Microbiol. Infect. (2001) [Pubmed]
  10. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Drusano, G.L., D'Argenio, D.Z., Preston, S.L., Barone, C., Symonds, W., LaFon, S., Rogers, M., Prince, W., Bye, A., Bilello, J.A. Antimicrob. Agents Chemother. (2000) [Pubmed]
  11. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Drusano, G.L., Preston, S.L., Van Guilder, M., North, D., Gombert, M., Oefelein, M., Boccumini, L., Weisinger, B., Corrado, M., Kahn, J. Antimicrob. Agents Chemother. (2000) [Pubmed]
  12. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. Drusano, G.L. J. Chemother (2000) [Pubmed]
  13. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Drusano, G.L., Stein, D.S. Antimicrob. Agents Chemother. (1998) [Pubmed]
  14. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. Drusano, G.L., Bilello, J.A., Stein, D.S., Nessly, M., Meibohm, A., Emini, E.A., Deutsch, P., Condra, J., Chodakewitz, J., Holder, D.J. J. Infect. Dis. (1998) [Pubmed]
  15. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Drusano, G.L., D'Argenio, D.Z., Symonds, W., Bilello, P.A., McDowell, J., Sadler, B., Bye, A., Bilello, J.A. Antimicrob. Agents Chemother. (1998) [Pubmed]
 
WikiGenes - Universities